Sutent 25 mg hard capsules
Sponsors
AstraZeneca AB, F. Hoffmann-La Roche AG, Bristol-Myers Squibb Services Unlimited Company, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Incyte Corp.
Conditions
Advanced MalignanciesAdvanced soft tissue and bone sarcomasAdvanced solid tumorLocally advanced/metastatic renal cell carcinomaMET-drivenMultiple myelomaNon-Hodgkin lymphomaPan tumor
Phase 1
Phase 2
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Start: 2016-07-25Target: 3000Updated: 2025-12-19
Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
RecruitingCTIS2023-506914-32-00
Start: 2020-05-05Target: 307Updated: 2026-01-19
Phase 3
A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)
CompletedCTIS2024-512016-22-00
Start: 2017-12-27End: 2025-06-04Target: 5Updated: 2025-06-02
SAMETA A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC) (SAMETA)
RecruitingCTIS2022-503105-38-00
Start: 2021-10-22Target: 62Updated: 2025-06-06
An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B)
Active, not recruitingCTIS2023-506184-34-00
Start: 2019-08-09Target: 104Updated: 2025-11-10